A Double-Blind, Placebo-Controlled, Randomised, Phase II Study Evaluating the Efficacy and Safety of Addition of Continuous Multiple Line Bevacizumab Treatment to Lomustine in Second (2nd)-Line Followed by Standard of Care (SOC) in Third (3rd)-Line and Beyond Compared to Addition of Placebo, Following First Progression of Disease (PD1) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
At a glance
- Drugs Bevacizumab (Primary) ; Lomustine; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms TAMIGA
- Sponsors Roche
- 30 Jun 2019 Trial has been discontinued in UK, according to European Clinical Trials Database record.
- 27 Jul 2017 Status changed from active, no longer recruiting to completed.
- 22 Jun 2017 event This trial has been completed in Austria (End date:2017-05-05).